tiprankstipranks
Trending News
More News >
Hydrix Limited (AU:HYD)
ASX:HYD
Australian Market

Hydrix Limited (HYD) AI Stock Analysis

Compare
2 Followers

Top Page

AU:HYD

Hydrix Limited

(Sydney:HYD)

Select Model
Select Model
Select Model
Neutral 44 (OpenAI - 5.2)
Rating:44Neutral
Price Target:
AU$0.02
▲(60.00% Upside)
Action:UpgradedDate:01/10/26
The score is constrained primarily by weak financial performance, including persistent losses and negative equity. Technicals are comparatively stronger with price above major moving averages and a positive MACD, but overbought RSI limits upside. Valuation is also pressured by a negative P/E and no dividend yield data.
Positive Factors
High gross profit margin
A 94.44% gross margin indicates the core products or services retain strong direct-margin economics. That structural margin provides room to cover fixed costs and fund R&D or sales investment, improving the odds of recovering profitability if revenue stabilizes.
Improving free cash flow growth
A 45.46% improvement in free cash flow growth signals better cash conversion or working-capital management. Sustained FCF improvement is durable because it boosts internal funding capacity, reduces dependency on external financing, and supports reinvestment or deleveraging.
Lean workforce and operating flexibility
A small headcount (55 employees) suggests a lean cost base and operational agility. Over a multi-month horizon this structural lightness can allow faster reallocation of resources, lower fixed payroll burden, and quicker scaling of profitable product lines as demand recovers.
Negative Factors
Negative shareholders' equity
Negative equity reflects accumulated losses and creates solvency and covenant risk. Structurally, it constrains the company's ability to raise equity or debt on favorable terms, increases refinancing risk, and can limit strategic options over the coming months.
Declining revenue trend
A year-over-year revenue decline (-2.24%) signals weakening top-line momentum. Persistently falling revenues reduce operating leverage, strain margins and cash flow, and make it harder to absorb fixed costs—threatening structural viability absent new product or market gains.
Persistent losses and negative operating cash flow
Ongoing net losses and negative operating cash flow mean the business is burning cash despite FCF improvement. Over months this erodes liquidity, forces reliance on external financing, and limits investment in growth initiatives, worsening solvency and strategic flexibility.

Hydrix Limited (HYD) vs. iShares MSCI Australia ETF (EWA)

Hydrix Limited Business Overview & Revenue Model

Company DescriptionHydrix Limited provides product design, engineering, and regulatory services in Australia, Singapore, Europe, North America, and internationally. It operates through two segments: Hydrix Services and Hydrix Medical. It provides cardiovascular products, such as The GUARDIAN, a cardiac monitoring and alerting device that reduces the stresses of living; Phyzhon PHYRARI FFR-Wire enables cardiologists to combine diagnosis procedures with delivery of therapy including stents; and LUDO, a customizable plug-and-play platform that provides critical tools to start MCS pump development. The company also offers a range of services, including product development, regulatory and clinical consulting, and technology commercialization. It serves medical, consumer, industrial, utilities, defense, aerospace, and mining industries. The company was formerly known as Panorama Synergy Limited and changed its name to Hydrix Limited in November 2018. Hydrix Limited was incorporated in 1993 and is headquartered in Mulgrave, Australia
How the Company Makes MoneyHydrix Limited generates revenue through multiple streams, primarily by selling its medical devices and software solutions to hospitals, clinics, and healthcare providers. The company also earns income from engineering services, which include product development and consulting for third-party clients in the medical field. Additionally, Hydrix may establish partnerships with other healthcare technology firms to co-develop products or share expertise, further contributing to its revenue. The company's ability to secure contracts and maintain relationships with key stakeholders in the healthcare industry is crucial for its financial performance.

Hydrix Limited Financial Statement Overview

Summary
Weak fundamentals: declining revenue (-2.24%), negative net profit and EBIT margins, and a balance sheet with negative equity signaling solvency risk. Free cash flow growth improved (45.46%), but operating cash flow remains negative, limiting the benefit.
Income Statement
35
Negative
Hydrix Limited has experienced a decline in revenue over the past year, with a negative revenue growth rate of -2.24%. The company is also facing challenges in profitability, as indicated by a negative net profit margin and EBIT margin. Although the gross profit margin is relatively high at 94.44%, the overall profitability is hindered by significant net losses.
Balance Sheet
20
Very Negative
The balance sheet reveals a concerning financial structure with negative stockholders' equity, resulting in an undefined debt-to-equity ratio. The company's return on equity is negative, indicating losses relative to shareholder investment. The equity ratio is also negative, highlighting potential solvency issues.
Cash Flow
40
Negative
Hydrix Limited shows some improvement in free cash flow growth at 45.46%, but operating cash flow remains negative, indicating ongoing cash flow challenges. The free cash flow to net income ratio is not meaningful due to negative net income, suggesting difficulties in generating cash relative to earnings.
BreakdownJun 2025Jun 2024Jun 2023Jun 2022Jun 2021
Income Statement
Total Revenue10.09M10.61M13.16M10.33M7.45M
Gross Profit9.53M9.79M-638.73K-3.31M-6.46M
EBITDA-1.40M-7.92M1.30M-4.05M-6.34M
Net Income-2.92M-9.56M-396.93K-5.55M-9.78M
Balance Sheet
Total Assets8.35M8.62M14.58M15.94M19.38M
Cash, Cash Equivalents and Short-Term Investments297.88K914.27K1.15M1.94M6.65M
Total Debt7.98M7.61M4.73M5.40M5.97M
Total Liabilities14.39M11.98M8.22M12.66M13.67M
Stockholders Equity-6.04M-3.36M6.35M3.28M5.71M
Cash Flow
Free Cash Flow-535.13K-1.91M-3.32M-6.75M-3.35M
Operating Cash Flow-527.01K-1.89M-3.12M-6.58M-2.86M
Investing Cash Flow-54.20K-53.43K-209.71K-306.65K-641.56K
Financing Cash Flow-36.31K1.71M2.16M1.72M7.53M

Hydrix Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.01
Price Trends
50DMA
0.02
Positive
100DMA
0.02
Positive
200DMA
0.02
Positive
Market Momentum
MACD
<0.01
Positive
RSI
73.06
Negative
STOCH
166.67
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HYD, the sentiment is Positive. The current price of 0.01 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 73.06 is Negative, neither overbought nor oversold. The STOCH value of 166.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:HYD.

Hydrix Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
$37.18B12.37-10.20%1.83%8.50%-7.62%
50
Neutral
AU$17.72M-1.31-135.89%-21.60%-657.00%
44
Neutral
AU$4.64M-1.27-4.86%64.36%
44
Neutral
AU$35.09M-6.44-78.66%-13.40%4.76%
43
Neutral
AU$7.60M-26.58%
42
Neutral
AU$4.32M-1.57-23.31%2.15%-900.00%
41
Neutral
AU$5.07M-0.39-51.64%-21.74%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:HYD
Hydrix Limited
0.02
>-0.01
-15.00%
AU:X2M
X2M Connect Limited
0.01
-0.01
-50.00%
AU:DVL
dorsaVi Limited
0.03
0.02
190.00%
AU:BCC
Beam Communications Holdings Limited
0.21
0.12
150.00%
AU:SIS
Simble Solutions Ltd.
AU:KNO
Knosys Ltd.
0.02
-0.02
-50.00%

Hydrix Limited Corporate Events

Hydrix Swings to Deeper Half-Year Loss as Project Timing Hits Revenue
Feb 27, 2026

Hydrix Limited reported a 14% decline in half-year revenues to $4.84 million for the period ended 31 December 2025, reflecting delays in new client project starts and the completion of existing development programs. The company does not plan to pay a dividend, highlighting a cautious capital stance amid softer operating performance and project timing challenges.

The loss after tax attributable to owners widened sharply to $2.34 million, a 268% deterioration from the prior corresponding period, as net tangible assets per share swung from a positive 1.14 cents to negative 3.37 cents. Cash used in operating activities was marginal at $22,383 versus prior inflows, underscoring tighter operating conditions, while the reviewed interim financial statements confirm the depth of the earnings and balance sheet pressure on shareholders.

The most recent analyst rating on (AU:HYD) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Hydrix Limited stock, see the AU:HYD Stock Forecast page.

Hydrix Corrects Quarterly Cash Flow Filing After Receipts Error
Feb 2, 2026

Hydrix Limited has lodged an amended Appendix 4C cash flow report for the quarter ended 31 December 2025 after identifying a typographical error in its previously released document. The correction relates to receipts from customers, which were originally overstated and have now been adjusted, signalling a clarification of the company’s reported operating cash inflows and ensuring stakeholders have accurate financial information for assessing its recent trading performance and cash position.

The most recent analyst rating on (AU:HYD) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Hydrix Limited stock, see the AU:HYD Stock Forecast page.

Hydrix Wins A$2.5m Contract on SynCardia’s Next-Generation Artificial Heart
Jan 7, 2026

Hydrix has secured an initial A$2.5 million contract with SynCardia Systems, a subsidiary of Picard Medical, to commence development of the next-generation fully implantable Total Artificial Heart, known as the Emperor. The multi-stage, multiyear program will see Hydrix design the controller and key subsystems using advanced electronics, software, mechanical and safety-critical engineering, reinforcing its credentials in mechanical circulatory support systems and positioning the company as a preferred global partner for complex cardiovascular device development, while SynCardia retains overall system architecture, regulatory and clinical leadership for the platform.

The most recent analyst rating on (AU:HYD) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Hydrix Limited stock, see the AU:HYD Stock Forecast page.

Hydrix Limited Announces Cessation of Securities
Dec 2, 2025

Hydrix Limited announced the cessation of several securities due to various reasons, including the lapse of conditional rights and the expiry of options without exercise. This move indicates a shift in the company’s financial strategy, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (AU:HYD) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Hydrix Limited stock, see the AU:HYD Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 10, 2026